Abbott Receives Health Canada Approval For Xience V Drug Eluting Stent
For the treatment of coronary artery disease
Abbott has received approval from Health Canada for the Xience V Everolimus Eluting Coronary Stent System, for the treatment of coronary artery disease (CAD).
Reportedly, Xience V is the only drug eluting stent to have demonstrated superiority over the Taxus Paclitaxel-Eluting Coronary Stent System (Taxus) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
The Xience V drug coated stent is used to treat CAD by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner over time, to help prevent the artery from becoming blocked again following the stent procedure.
Robert Hance, senior vice president of vascular at Abbott, said: Xience V represents a major advancement in the treatment of heart disease, based upon its ease of use and consistently strong performance across all clinical trials.We look forward to launching Xience V immediately in Canada to meet physician demand for this much-awaited drug eluting stent technology.
Related Insight
Suppliers Directory
TBM Consulting Group - Lean Sigma Manufacturing Services
The global fallout from the real estate and banking crisis has impacted economies worldwide since 2009 and is likely to carry over well into 2012. The drop in consumer demand, capital spending cuts, layoffs, rising unemployment, the spectre of inflation and erratic equity markets has put intense pressure on margins and heightened everyone’s focus on cutting costs.
Suppliers
Hovione - API Development
When you really care about quality and performance, Hovione is your API
Hovione is an international company with over 50 years’ experience in API development and compliant manufacture. With FDA inspected sites in the US, China, Ireland, and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
Suppliers
MeadWestvaco MWV - Healthcare Packaging and Dispensing Solutions
MWV is a global leader in healthcare packaging and packaging solutions.
Suppliers
Softbox - Temperature Control Packaging Systems
Softbox design and manufacture temperature control packaging and cold chain - shipping containers for the distribution of biotech, biomedical, clinical trial and finished pharmaceutical products.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Revolutionary Plasma Technology from Presspart.
Published by Presspart
White Papers
Quality Assurance
Published by A-Consult
White Papers
How to Design a Clinical Data Warehouse
Published by NNIT
White Papers
Knowing Your Product’s Disintegration Curve Is Key to Quality
Published by Dr Schleuniger Pharmatron
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.